SCHEMBL2285143

SCHEMBL2285143

Cc1cc(O)c(C(=O)C=Cc2cccc(C(=O)NS(C)(=O)=O)c2)c(=O)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.47
HTT P42858 5/20 0.47
MAPT P10636 4/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
NPSR1 Q6W5P4 2/20 0.47
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
PAX8 Q06710 1/20 0.41
SLC5A1 P13866 1/20 0.40
SLC5A2 P31639 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PADI4 Q9UM07 1/20 0.39
P4HB P07237 2/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2285140 1.00 LMNA (0.47) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2281489 0.83 NPC1 (0.43) MAPTNPSR1KMT2AHDAC3HDAC1
SCHEMBL2279537 0.83 LMNA (0.47) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2279543 0.83 LMNA (0.47) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2281492 0.83 NPC1 (0.43) MAPTNPSR1KMT2AHDAC3HDAC1
SCHEMBL2284323 0.82 LMNA (0.43) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2275750 0.82 LMNA (0.43) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2275754 0.82 LMNA (0.43) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2284334 0.82 LMNA (0.43) LMNAHTTMAPTSMN1; SMN2NPSR1
SCHEMBL2280689 0.81 LMNA (0.43) LMNAHTTMAPTSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 LMNA 537/4885HTT 4798/4885MAPT 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.